Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA – Get Free Report) major shareholder Orbimed Advisors Llc sold 860,123 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $45.36, for a total transaction of $39,015,179.28. Following the transaction, the insider directly owned 219,405 shares of the company’s stock, valued at $9,952,210.80. The trade was a 79.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Monday, June 15th, Orbimed Advisors Llc sold 281,408 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $45.02, for a total transaction of $12,668,988.16.
Bitwise MARA Option Income Strategy ETF Stock Down 3.2%
NYSEARCA IMRA opened at $17.03 on Thursday. The stock has a market cap of $3.24 million, a P/E ratio of 340.60 and a beta of 2.88. The company’s 50-day simple moving average is $16.69 and its 200 day simple moving average is $15.74. Bitwise MARA Option Income Strategy ETF has a twelve month low of $11.99 and a twelve month high of $54.94.
Bitwise MARA Option Income Strategy ETF Company Profile
IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.
See Also
- Five stocks we like better than Bitwise MARA Option Income Strategy ETF
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Bitwise MARA Option Income Strategy ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bitwise MARA Option Income Strategy ETF and related companies with MarketBeat.com's FREE daily email newsletter.
